{"id":"piperacillin-tazobactam-injection","safety":{"commonSideEffects":[{"rate":"3-5%","effect":"Diarrhea"},{"rate":"2-4%","effect":"Nausea"},{"rate":"1-3%","effect":"Vomiting"},{"rate":"2-4%","effect":"Rash"},{"rate":"2-3%","effect":"Phlebitis at injection site"},{"rate":"1-2%","effect":"Headache"},{"rate":"<1%","effect":"Allergic reactions including anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is a broad-spectrum beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by bacterial beta-lactamase enzymes, extending its spectrum to include beta-lactamase-producing organisms. Together, they provide enhanced coverage against gram-positive, gram-negative, and anaerobic bacteria.","oneSentence":"Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing the antibiotic to overcome resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:31.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and lower respiratory tract infections"},{"name":"Nosocomial pneumonia"},{"name":"Febrile neutropenia in cancer patients"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT06972537","phase":"NA","title":"A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-07-24","conditions":"Pneumonia","enrollment":42},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06076200","phase":"","title":"Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations","status":"RECRUITING","sponsor":"Shandong University","startDate":"2023-09-30","conditions":"Early-Onset Neonatal Sepsis","enrollment":50},{"nctId":"NCT05981079","phase":"PHASE4","title":"Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-07-31","conditions":"Late-Onset Neonatal Sepsis","enrollment":332},{"nctId":"NCT05943223","phase":"PHASE2","title":"Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)","status":"UNKNOWN","sponsor":"McMaster Children's Hospital","startDate":"2024-01","conditions":"Appendicitis Perforated","enrollment":16},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT04895657","phase":"PHASE4","title":"Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-07-27","conditions":"Gram-Negative Infections","enrollment":56},{"nctId":"NCT03583749","phase":"","title":"Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2019-08-07","conditions":"Antimicrobials, Subcutaneous Injection, Antibiotic","enrollment":150},{"nctId":"NCT00924742","phase":"NA","title":"A Single-Dose Pharmacokinetics Study of Tapimycin Injection","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2009-03","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":31,"reaction":"PYREXIA"},{"count":21,"reaction":"CONDITION AGGRAVATED"},{"count":20,"reaction":"RASH"},{"count":16,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":15,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":14,"reaction":"THROMBOCYTOPENIA"},{"count":13,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":13,"reaction":"GAMMA-GLUTAMYLTRANSFERASE INCREASED"},{"count":13,"reaction":"NEUTROPENIA"},{"count":13,"reaction":"RENAL FAILURE ACUTE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Piperacillin / Tazobactam Injection","genericName":"Piperacillin / Tazobactam Injection","companyName":"Rambam Health Care Campus","companyId":"rambam-health-care-campus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin/Tazobactam Injection is a small molecule that inhibits bacterial penicillin-binding protein. It is used to treat various bacterial infections, including Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia, Early-Onset Neonatal Sepsis, and Urinary Tract Infections.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}